All lobbying filings

Forbes-Tate

Forbes-Tate filed a Q2 report for Sanofi U.S. on July 17, 2025, reporting $50,000 in lobbying income.

Lobbying for Sanofi U.S. · Multinational Pharmaceutical Company

As filed: FORBES-TATE for SANOFI U.S.

All filings by Forbes-Tate · Everything Sanofi U.S. has reported

Filing · LD-2 quarterly report Q2 report

Reporting period

2nd Quarter 2025

Apr 1 - June 30 · Posted Jul 17, 2025

Income

$50,000

What the client paid this registrant for the period.

Client based in

District of Columbia

Official filing document

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 3

Health Issues

Issues related to prescription drug pricing; Issues related to Section 340B of the Public Health Service Act (PL 78-410); Drug pricing issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to flu and RSV vaccines.

Medicare/Medicaid

Issues related to prescription drug pricing, including the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to Section 340B of the Public Health Service Act (PL 78-410); Issues related to pharmacy benefit managers.

Taxation/Internal Revenue Code

Issues related to orphan drug tax credit; Issues related to the excise tax for the Vaccine Injury Compensation Fund.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.